Lunit

Lunit P/B

The P/B (Price-to-Book Ratio) of Lunit (328130.KQ) as of Oct 16, 2026 is 187.75. In the previous year, P/B (Price-to-Book Ratio) was 201.67 — a change of -6.90% (lower).

P/B

187.75

YoY

-6.90%

Last updated:

P/B (Price-to-Book Ratio) of Lunit is 2024 187.75 . P/B (Price-to-Book Ratio) of Lunit was 2023 201.67 . It decreases by -6.90% lower compared to the previous year.

The Lunit P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2019
-20.63 KRW
Jan 1, 2020
-9.30 KRW
Jan 1, 2021
595.94 KRW
Jan 1, 2022
182.91 KRW
Jan 1, 2023
201.67 KRW
Jan 1, 2024
187.75 KRW
The Lunit P/B history
YEARP/BYoY
187.75-6.90%
201.67+10.26%
182.91-69.31%
595.94-6,511.31%
-9.30-54.93%
-20.63—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lunit Stock analysis

What does Lunit do? Lunit Inc is a South Korean company headquartered in Seoul, operating within the Health Care sector. The company has 293 employees and went public on July 21, 2022, with its ticker listed as 328130.KQ and ISIN KR7328130000. Lunit provides software solutions for medical diagnostic imaging services, focusing on the development and supply of AI-powered medical software. Its offerings include cancer diagnostic aid solutions, cancer early detection solutions, and cancer risk prediction solutions. The company's technology leverages artificial intelligence to enhance diagnostic capabilities in healthcare settings. Lunit's website is www.lunit.io, where further information about its services and solutions can be accessed. The company operates in the Health Care industry, specifically targeting medical imaging and AI-driven diagnostic tools. As of the latest available data, Lunit is engaged in the development and commercialization of AI-based medical software, aiming to improve the accuracy and efficiency of cancer-related diagnostics. The firm's IPO date marks its transition to a publicly traded company, reflecting its growth and market position in the healthcare technology space. Lunit's focus on AI applications in medical imaging positions it as a key player in the digital health sector, particularly within the Korean market and beyond. The company's solutions are designed to support healthcare professionals in making more informed diagnostic decisions, potentially reducing the time and resources required for cancer detection and treatment planning. Lunit is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lunit stock

P/B (Price-to-Book Ratio) of Lunit is 187.75 in 2024.

P/B (Price-to-Book Ratio) of Lunit changed from 201.67 to 187.75, representing a -6.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Lunit since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Lunit with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Lunit

All Key Metrics — Lunit